THERAMEX
23.12.2021 15:08:08 CET | Business Wire | Press release
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an agreement with Enzene Biosciences Limited to develop, register and commercialise a biosimilar drug of Roche’s reference medicine RoActemra® (Tocilizumab). Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis. It is planned to be commercialised from 2026 in Europe, the UK, Switzerland, and Australia.
Theramex’s Tocilizumab product will be available in parenteral vials, subcutaneous prefilled syringes and autoinjectors. The reference product RoActemra® is indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with methotrexate; moderate to severe RA adult patients who have not responded well/intolerant to DMARDs or Anti-TNFs; active systemic juvenile idiopathic arthritis in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids; juvenile idiopathic polyarthritis in patients 2 years of age and older unresponsive to MTX; treatment of Giant Cell Arteritis in adults; and chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.
Rheumatoid arthritis is a chronic condition that causes pain, swelling and stiffness in the joints. The condition usually affects the hands, feet and wrists. There may be periods where symptoms become worse, known as flares. A flare can be difficult to predict, but with treatment it's possible to decrease the number of flares and minimise or prevent long-term damage to the joints. Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss1 .
“Rheumatoid arthritis affects more women than men, so the addition of this biosimilar drug to our existing Rheumatology portfolio continues our strategic determination to improve access and affordability of important treatments for women. We are excited to expand our focus in Rheumatology to now include rheumatoid arthritis to help even more patients with bone diseases and joint pain”, said Theramex CEO Robert Stewart .
Dr. Himanshu Gadgil , Enzene's Whole Time Director said, "The development of Enzene’s Tocilizumab, through our innovative efforts in the manufacturing of monoclonal antibodies, marks another highlight in a series of endeavours driven by our mission to provide affordable and expanded access to crucial medicines. Our partnership with Theramex bolsters our mission to bring affordable healthcare to patients across the world”.
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.
About Enzene Biosciences Ltd.
Enzene is an innovation-driven biotech company, a subsidiary of Alkem Laboratories Ltd. (One of the top five pharmaceutical companies in India*) located in Pune, India. Enzene's focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services.
(*as per the latest IQVIA data of MAT July 2021)
For more information on Enzene Biosciences Ltd., please visit www.enzene.com
For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com
1 https://www.nhs.uk/conditions/rheumatoid-arthritis/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005258/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carbon Measures Opens Singapore Office and Launches First In-Country Pilot to Advance Industrial Decarbonization in Hard-to-Abate Sectors12.11.2026 12:00:00 CET | Press release
Today, at COP31, Carbon Measures announced the establishment of its Singapore office, with support from the Singapore Economic Development Board (EDB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112827071/en/ Carbon Measures opens Singapore office and launches first in-country pilot to advance industrial decarbonization in hard-to-abate sectors. The Singapore office will serve as Carbon Measures’ Asia-Pacific hub, expanding its technical expertise and knowledge capabilities while strengthening engagement with key stakeholders across the region. The office will focus on advancing industrial decarbonization policies for hard-to-abate sectors, convening companies, nonprofit organizations, academic institutions and other partners to guide the Pilot’s development and implementation. “We welcome Carbon Measures’ establishment of its first office in the region. By piloting new approaches for product-level carbon accounting,
Focused Support Delivers Link 16 to Royal Netherlands Air and Space Force MQ-9 Fleet With Cavok STRIKE12.11.2026 12:00:00 CET | Press release
Focused Support LLC today announced the successful deployment of Cavok® STRIKE to the Royal Netherlands Air and Space Force (RNLASF), providing its MQ-9 fleet with enhanced Link 16 participation capabilities without requiring modifications to the aircraft. The deployment represents a significant advance in integrating remotely piloted aircraft into the shared tactical picture, improving situational awareness, interoperability, and coordination across joint and coalition forces. The installation marks a key milestone for Focused Support as Cavok STRIKE expands into European military operations. Integrated within the Cavok Mission Ecosystem, STRIKE addresses a persistent tactical challenge: extending Link 16 to non-traditional participants without costly or complex aircraft modifications. Focused Support Founder and CEO, Jonathan Shill, remarked, “Two decades ago we asked for Link 16 on the MQ-1 Predator but were denied because the 8 lb. terminal represented a half hour of time on statio
Ahead of Frieze Abu Dhabi, 421 Arts Campus Spotlights Emerging Artistic Practices12.11.2026 11:15:00 CET | Press release
As Abu Dhabi prepares to welcome the international art community for the inaugural Frieze Abu Dhabi this November, 421 Arts Campus presents two exhibitions highlighting artistic experimentation, research, and emerging creative practices in the UAE and wider region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112518634/en/ Juma Alhaj, Revelation, 2026 at 421 Arts Campus. Courtesy of 421 and the artist. (Photography by: Ismail Noor, Seeing Things) On view until 10 January 2027, the exhibitions bring together distinct artistic approaches, from Juma Alhaj’s exploration of reflection and self-discovery to an examination of how knowledge is formed and shared through informal modes of communication. Revelation, the first institutional solo exhibition by Emirati artist Juma Alhaj, marks a significant evolution in his practice. Grounded in reading, journaling, and philosophical inquiry, the exhibition explores reflection, solit
a2z Radiology AI Receives EU MDR Certification for AI That Detects 182 Findings Across Head, Chest, Abdomen and Pelvis CT12.11.2026 09:00:00 CET | Press release
a2z-Drafter is the first AI product certified under the EU Medical Device Regulation to support both detection and report drafting across head, chest, abdomen and pelvis CT. a2z Radiology AI Inc. today announced that a2z-Drafter has been certified under the EU Medical Device Regulation (MDR). The software supports triage, detection and report drafting on CT scans of the head, chest, abdomen and/or pelvis. “Radiology teams have had to piece together separate AI tools for each condition and body region,” said Samir Rajpurkar, co-founder and CEO of a2z Radiology AI. “a2z-Drafter is one product that works on head, chest and abdomen-pelvis CT scans and gives the radiologist a structured starting point for the report. This certification lets us bring that to radiology teams in the European Union.” a2z-Drafter detects 182 validated radiological findings on CT studies of the head, chest, abdomen and/or pelvis, with supplementary attributes for selected findings. The findings span acute conditi
KiddeFenwal Secures A2P System Certification from Centre National de Prévention et de Protection in France12.11.2026 09:00:00 CET | Press release
Assurance Prévention Protection benchmark from CNPP marks key milestone in the global adoption of NATURA™ inert gas fire suppression system.Certification elevates proven technology that conserves water while safeguarding assets and minimizing downtime. KiddeFenwal, the global leader in fire protection and safety controls, has received an Assurance Prévention Protection (A2P) System Certification for its NATURA™ inert gas fire suppression system. The designation from France’s Centre National de Prévention et de Protection (CNPP), one of the most respected fire safety testing and certification organizations in Europe, illustrates how KiddeFenwal is expanding the reach of its industry-leading technologies throughout the world with the support of independent, third-party evaluators. “KiddeFenwal is grateful to CNPP for standing behind our proven NATURA™ system,” said Rekha Agrawal, CEO of KiddeFenwal. “The certification enables our systems to protect the facilities and institutions that ma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom